CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
TAK-925 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04091438
NCT04091438Phase 1Completed
CompareCT.gov

A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia

Millennium Pharmaceuticals, Inc.·interventional·Posted Sep 16, 2019·Updated Sep 26, 2023

In Brief

A Phase 1 clinical trial evaluating TAK-925 and TAK-925 Placebo for Idiopathic Hypersomnia. Completed, enrolled 28 participants across 22 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK-925 to adult participants with idiopathic hypersomnia (IH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Hypersomnia
CountriesJapan, United States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedSep 16, 2019
Enrollment StartJan 26, 2020
Primary CompletionNov 19, 2020
Study CompletionNov 23, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.8 years ago

Interventions

TAK-925drug

TAK-925 IV infusion.

TAK-925 Placebodrug

TAK-925 placebo-matching IV infusion.